Correlation of abnormal RB, p16(ink4a), and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 791-800

  Geradts, Joseph ^a,d   Fong, Kwun M ^b   Zimmerman, Paul V ^b   Maynard, Robert ^a   Minna, John D ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CHROMOSOME 3P; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOMES, HUMAN, PAIR 3; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032926002     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
2. Liggett, W. H., Jr., and Sidransky, D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol., 16: 1197-1206, 1998.
3. Salgia, R., and Skarin, A. T. Molecular abnormalities in lung cancer. J. Clin. Oncol., 16: 1207-1217, 1998.
4. Sekido, Y., Fong, K., and Minna, J. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim. Biophys. Acta., 1378: F21-F59, 1998.
5. Graziano, S. L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer, 17: S37-S58, 1997.
6. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
7. Reissmann, P. T., Koga, H., Takahashi, R., Figlin, R. A., Holmes, E. C., Piantadosi, S., Cordon-Cardo, C., and Slamon, D. J. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene, 8: 1913-1919, 1993.
8. Dosaka-Akita, H., Hu, S. X., Fujino, M., Harada, M., Kinoshita, I., Xu, H. J., Kuzumaki, N., Kawakami, Y., and Benedict, W. F. Altered retinoblastoma protein expression in non-small cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer (Phila.), 79: 1329-1337, 1997.
9. Xu, H. J., Quinlan, D. C., Davidson, A. G., Hu, S. X., Summers, C. L., Li, J., and Benedict, W. F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J. Natl. Cancer Inst., 86: 695-699, 1994.
10. INK4a expression in resected non-small cell lung tumors. Cancer Res., 56: 3415-3420, 1996.
11. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res., 56: 5557-5562, 1996.
12. Sakaguchi, M., Fujii, Y., Hirabayashi, H., Yoon, H. E., Komoto, Y., Oue, T., Kusafuka, T., Okada, A., and Matsuda, H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer, 65: 442-445, 1996.
13. INK4 expression in non-small cell lung carcinoma. Cancer (Phila.), 80: 389-395, 1997.
14. Nishio, M., Koshikawa, T., Kuroishi, T., Suyama, M., Uchida, K., Takagi, Y., Washimi, O., Sugiura, T., Ariyoshi, Y., Takahashi, T., Ueda, R., and Takahashi, T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J. Clin. Oncol., 14: 497-502, 1996.
15. Fujino, M., Dosaka-Akita, H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995.
16. Dalquen, P., Sauter, G., Torhorst, J., Schultheiss, E., Jordan, P., and Lehmann, S. Nuclear p53 overexpression is an independent prognostic parameter in. J. Pathol., 178: 53-58, 1996.
17. Kawasaki, M., Noguchi, M., Morikawa, A., Matsuno, Y., Yamada, T., Hirohashi, S., Kondo, H., and Shimosato, Y. Nuclear p53 accumulation by small-sized adenocarcinomas of the lung. Pathol. Int., 46: 486-490, 1996.
18. Sekido, Y., Bader, S., Latif, F., Gnarra, J. R., Gazdar, A. F., Linehan, W. M., Zbar, B., Lerman, M. I., and Minna, J. D. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene, 9: 1599-1604, 1994.
19. Sozzi, G., Veronese, M. L., Negrini, M., Baffa, R., Cotticelli, M. G., Inoue, H., Tornielli, S., Pilotti, S., DeGregorio, L., Pastorino, U., Pierotti, M. A., Ohta, M., Huebner, K., and Croce, C. M. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.
20. Fong, K., Biesterveld, E., Virmani, A., Wistuba, I., Sekido, Y., Bader, S., Ahmadian, M., Ong, S., Rassool, F., Zimmerman, P., Giaccone, G., Gazdar, A., and Minna, J. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res., 57: 2256-2267, 1997.
21. Shimizu, E., Coxon, A., Otterson, G. A., Steinberg, S. M., Kratzke, R. A., Kim, Y. W., Fedorko, J., Oie, H., Johnson, B. E., Mulshine, J. L., Minna, J. D., Gazdar, A. F., and Kaye, F. J. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9: 2441-2448, 1994.
22. Fong, K. M., Zimmerman, P. V., and Smith, P. J. Correlation of loss of heterozygosity at 11p with tumor progression and survival in non-small cell lung cancer. Genes Chromosomes Cancer, 10: 183-189, 1994.
23. Fong, K. M., Zimmerman, P. V., and Smith, P. J. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res., 55: 220-223, 1995.
24. Fong, K. M., Zimmerman, P. V., and Smith, P. J. Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res., 55: 28-30, 1995.
25. Fong, K. M., Kida, Y., Zimmerman, P. V., Ikenaga, M., and Smith, P. J. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res., 55: 4268-4272, 1995.
26. Wen, S. F., Nodelman, M., Nared-Hood, K., Duncan, J., Geradts, J., and Shepard, H. M. Retinoblastoma protein monoclonal antibodies with novel characteristics. J. Immunol. Methods, 169: 231-240, 1994.
27. Geradts, J., Kratzke, R. A., Niehans, G. A., and Lincoln, C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
28. Geradts, J., Kratzke, R. A., Crush-Stanton, S., Wen, S. F., and Lincoln, C. E. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod. Pathol., 9: 339-347, 1996.
29. Don, R., Cox, P., Wainwright, B., Baker, K., and Mattick, J. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res., 19: 4008, 1991.
30. Fong, K. M., Zimmerman, P. V., and Smith, P. J. KRAS codon 12 mutations in Australian non-small cell lung cancer. Aust. N. Z. J. Med., 28: 184-189, 1998.
31. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res., 55: 1448-1451, 1995.
32. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
33. Tanaka, H., Fujii, Y., Hirabayashi, H., Miyoshi, S., Sakaguchi, M., Yoon, H. E., and Matsuda, H. Disruption of the RB pathway and cell-proliferative activity in non-small-cell lung cancers. Int. J. Cancer, 79: 111-115, 1998.
34. Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T., and Nakajima, T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int. J. Cancer, 79: 215-220, 1998.
35. Harpole, D. H., Jr., Herndon, J. E., 2nd, Wolfe, W. G., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
36. Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D., Robinson, R. A., Weiner, D., and Schwartz, D. A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest., 93: 516-520, 1994.
37. Gazzeri, S., Gouyer, V., Vour'ch, C., Brambilla, C., and Brambilla, E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene, 16: 497-504, 1998.
38. Marchetti, A., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Carnicelli, V., Tognoni, V., Filardo, A., Angeletti, C. A., and Bevilacqua, G. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J. Pathol., 181: 178-182, 1997.
39. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Gaeta, P., La Rocca, R., Merlo, G., Chella, A., Angeletti, C. A., Dalla Palma, P., and Bevilacqua, G. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int. J. Cancer, 75: 187-192, 1998.
40. Betticher, D. C., White, G. R., Vonlanthen, S., Liu, X., Kappeler, A., Altermatt, H. J., Thatcher, N., and Heighway, J. G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int. J. Cancer, 74: 556-562, 1997.
41. Bodner, S. M., Minna, J. D., Jensen, S. M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., Gazdar, A. F., and Linnoila, R. I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
42. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinha, G., Bleehen, N. M., and Rabbitts, P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989-1997, 1992.
43. Sugio, K., Kishimoto, Y., Virmani, A. K., Hung, J. Y., and Gazdar, A. F. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res., 54: 5811-5815, 1994.
44. Chung, G. T., Sundaresan, V., Hasleton, P., Rudd, R., Taylor, R., and Rabbitts, P. H. Sequential molecular genetic changes in lung cancer development. Oncogene, 11: 2591-2598, 1995.
45. Hung, J., Kishimoto, Y., Sugio, K., Virmani, A., McIntire, D. D., Minna, J. D., and Gazdar, A. F. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J. Am. Med. Assoc., 273: 558-563, 1995.
46. Kishimoto, Y., Sugio, K., Hung, J. Y., Virmani, A. K., McIntire, D. D., Minna, J. D., and Gazdar, A. F. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl. Cancer Inst., 87: 1224-1229, 1995.
47. Burke, L., Khan, M. A., Freedman, A. N., Gemma, A., Rusin, M., Guinee, D. G., Bennett, W. P., Caporaso, N. E., Fleming, M. V., Travis, W. D., Colby, T. V., Trastek, V., Pairolero, P. C., Tazelaar, H. D., Midthun, D. E., Liotta, L. A., and Harris, C. C. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res., 58: 2533-2536, 1998.
48. Mitsudomi, T., Oyama, T., Nishida, K., Ogami, A., Osaki, T., Sugio, K., Yasumoto, K., Sugimachi, K., and Gazdar, A. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin. Cancer Res., 2: 1185-1189, 1996.
49. Nelson, H. H., Wiencke, J. K., Gunn, L., Wain, J. C., Christiani, D. C., and Kelsey, K. T. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res., 58: 1804-1807, 1998.
50. Pifarre, A., Rosell, R., Monzo, M., De Anta, J. M., Moreno, I., Sanchez, J. J., Ariza, A., Mate, J. L., Martinez, E., and Sanchez, M. Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer. Br. J. Cancer, 75: 184-189, 1997.
51. Field, J. K., Neville, E. M., Stewart, M. P., Swift, A., Liloglou, T., Risk, J. M., Ross, H., Gosney, J. R., and Donnelly, R. J. Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. Br. J. Cancer, 74: 1968-1974, 1996.
52. Thiberville, L., Bourguignon, J., Metayer, J., Bost, F., Diarra-Mehrpour, M., Bignon, J., Lam, S., Martin, J. P., and Nouvet, G. Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. Int. J. Cancer, 64: 371-377, 1995.
53. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura, Y., Ueda, R., and Takahashi, T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.